Intra-oral formulations comprising soft anticholinergic zwitterions are useful for treating excessive drooling conditions in subjects, such as humans, suffering from sialorrhea. Preferably, at least one soft anticholinergic zwitterion is provided in an effective amount or concentration in an intra-oral formulation that inhibits excessive drooling resulting from a condition known as sialorrhea.
